PCSK9 gene mutations and low-density lipoprotein cholesterol

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 148-153

  Wu, Na Qiong ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Coronary heart disease; Dyslipidemia; Genetic variant; Proprotein convertase subtilisin like kexin type 9

Indexed keywords

EVOLOCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL HOMEOSTASIS; CHOLESTEROL METABOLISM; CLASSIFICATION; DRUG EFFICACY; DRUG TARGETING; GAIN OF FUNCTION MUTATION; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; LOSS OF FUNCTION MUTATION; NONHUMAN; PATHOPHYSIOLOGY; PCSK9 GENE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; BLOOD; GENETICS; MUTATION; PHYSIOLOGY;

CHOLESTEROL, LDL; HUMANS; MUTATION; POLYMORPHISM, GENETIC; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84896694715     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.043     Document Type: Review

References (43)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
2. Brautbar A., Ballantyne C.M. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol 2011, 8:253-265.
3. Cariou B., Le May C., Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011, 216:258-265.
4. Tibolla G., Norata G.D., Artali R., Meneghetti F., Catapano A.L. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011, 21:835-843.
5. Lambert G., Krempf M., Costet P. PCSK9: a promising therapeutic target for dyslipidemias?. Trends Endocrinol Metab 2006, 17:79-81.
6. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
7. Horton J.D., Cohen J.C., Hobbs H.H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007, 32:71-77.
8. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009, 50(Suppl.):S172-S177.
9. Abifadel M., Rabes J.P., Devillers M., et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009, 30:520-529.
10. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
11. Maxwell K.N., Breslow J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004, 101:7100-7105.
12. Park S.W., Moon Y.A., Horton J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004, 279:50630-50638.
13. Maxwell K.N., Fisher E.A., Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A 2005, 102:2069-2074.
14. Rashid S., Curtis D.E., Garuti R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005, 102:5374-5379.
15. Mayne J., Dewpura T., Raymond A., et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem 2011, 57:1415-1423.
16. Cohen J., Pertsemlidis A., Kotowski I.K., et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
17. Yue P., Averna M., Lin X., et al. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat 2006, 27:460-466.
18. Allard D., Amsellem S., Abifadel M., et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005, 26:497.
19. Timms K.M., Wagner S., Samuels M.E., et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004, 114:349-353.
20. Cohen J.C., Boerwinkle E., Mosley T.H., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
21. Hooper A.J., Marais A.D., Tanyanyiwa D.M., et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193:445-448.
22. Kotowski I.K., Pertsemlidis A., Luke A., et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006, 78:410-422.
23. Berge K.E., Ose L., Leren T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006, 26:1094-1100.
24. Scartezini M., Hubbart C., Whittall R.A., et al. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin Sci 2007, 113:435-441.
25. Kathiresan S., Melander O., Anevski D., et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008, 358:1240-1249.
26. Hallman D.M., Srinivasan S.R., Chen W., et al. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). Am J Cardiol 2007, 100:69-72.
27. Kostrzewa G., Broda G., Kurjata P., et al. Effect of protein convertase subtilisin/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population. Mol Genet Metab 2008, 94:259-262.
28. Strom T.B., Holla O.L., Cameron J., et al. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes. Clin Chim Acta 2010, 411:229-233.
29. Benn M., Nordestgaard B.G., Grande P., et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010, 55:2833-2842.
30. Cameron J., Holla O.L., Laerdahl J.K., et al. Characterization of novel mutations in the catalytic domain of the PCSK9 gene. J Int Med 2008, 263:420-431.
31. Noguchi T., Katsuda S., Kawashiri M.A., et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 2010, 210:166-172.
32. Aung L.H., Yin R.X., Miao L., et al. The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis 2011, 10:5.
33. Aung L.H., Yin R.X., Wu D.F., et al. Proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism interacts with alcohol consumption to modulate serum lipid levels. Int J Med Sci 2013, 10:124-132.
34. Hsu L.A., Teng M.S., Ko Y.L., et al. The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. Clin Chem Lab Med 2009, 47:154-158.
35. Ouguerram K., Chetiveaux M., Zair Y., et al. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol 2004, 24:1448-1453.
36. Kohli P., Desai N.R., Giugliano R.P., et al. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol 2012, 35:385-391.
37. Giugliano R.P., Desai N.R., Kohli P., et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380:2007-2017.
38. Raal F., Scott R., Somaratne R., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012, 126:2408-2417.
39. Desai N.R., Kohli P., Giugliano R.P., et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial. Circulation 2013, 128:962-969.
40. Chaparro-Riggers J., Liang H., DeVay R.M., et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012, 287:11090-11097.
41. Dubuc G., Chamberland A., Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
42. Guo Y.-L., Liu J., Xu R.-X., et al. Short-term impacts of low dose atorvastatin on serum proprotein convertase subtilisin/kexin type 2013, 33:877-883.
43. Liu J., Guo Y.-L., Zheng X., Xue R.-X., Li J.-J. Rapid effects of different lipid-lowering drugs on Proprotein convertase subtilisin kexin/type 9 in humans. Clin Lipidol 2013, 8:519-524.